Nomenclature: CRF2 receptor

Family: Corticotropin-releasing factor receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates. 

Contents

Gene and Protein Information
class B G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 411 7p21-p15 CRHR2 corticotropin releasing hormone receptor 2 10,23
Mouse 7 411 6 B3 Crhr2 corticotropin releasing hormone receptor 2 13,18,22,32
Rat 7 411 4q24 Crhr2 corticotropin releasing hormone receptor 2 25
Previous and Unofficial Names
CRH2
CRFR2
CRF-R2
CRF-RB
HM-CRF
CRF2
CRH-R2
Crf2r
CRF-R 2
CRF-R-2
CRFR-2
CRH-R 2
CRH-R-2
corticotrophin releasing hormone receptor 2
corticotropin releasing hormone receptor 2
corticotropin-releasing factor receptor 2
corticotropin-releasing factor receptor subtype 2
corticotropin-releasing hormone receptor 2
CRFR2alpha
CRFR2beta
CRF 2 receptor
Database Links
ChEMBL Target
Ensembl Gene
Entrez Gene
GPCRDB
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG Gene
OMIM
PharmGKB Gene
PhosphoSitePlus
Protein Ontology (PRO)
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene Hs.
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  CRFR2α extracellular domain in complex with Urocortin 1
PDB Id:  3N96
Ligand:  urocortin 1   This ligand is endogenous
Resolution:  2.75Å
Species:  Human
References:  26
Natural/Endogenous Ligands
CRF {Sp: Human, Mouse, Rat}
urocortin 1 {Sp: Human} , urocortin 1 {Sp: Mouse, Rat}
urocortin 2 {Sp: Rat} , urocortin 2 {Sp: Human} , urocortin 2 {Sp: Mouse}
urocortin 3 {Sp: Mouse, Rat} , urocortin 3 {Sp: Human}
Agonists
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[125I]urocortin 1 (mouse, rat) Hs Full agonist 10.0 pKd 28
pKd 10.0 [28]
[125I]sauvagine (frog) Hs Full agonist 9.6 – 9.8 pKd 8,12
pKd 9.6 – 9.8 [8,12]
urocortin 1 {Sp: Human} Hs Full agonist 9.0 – 9.6 pKd 8,12
pKd 9.0 – 9.6 [8,12]
urocortin 2 {Sp: Human} Mm Full agonist 9.3 pKd 22,29
pKd 9.3 [22,29]
urocortin 2 {Sp: Mouse} Mm Full agonist 9.2 pKd 22
pKd 9.2 [22]
urocortin 1 {Sp: Mouse, Rat} Mm Full agonist 8.7 – 9.4 pKd 12,14,22,28,35
pKd 9.0 – 9.4 [12,14,22,28,35]
pKd 8.7 – 9.2 [14,22,28]
urocortin 1 {Sp: Mouse, Rat} Hs Full agonist 8.6 – 9.4 pKd 12
pKd 8.6 – 9.4 [12]
urocortin 1 {Sp: Human} Mm Full agonist 8.8 pKd 14
pKd 8.8 [14]
urocortin 2 {Sp: Human} Rn Full agonist 8.8 pKd 22
pKd 8.8 [22]
urocortin 2 {Sp: Mouse} Rn Full agonist 8.7 pKd 22
pKd 8.7 [22]
urocortin 1 {Sp: Human} Rn Full agonist 8.7 pKd 14
pKd 8.7 [14]
urocortin 3 {Sp: Mouse, Rat} Mm Full agonist 8.7 pKd 22
pKd 8.7 [22]
urocortin 2 {Sp: Human} Hs Full agonist 8.5 – 8.6 pKd 8
pKd 8.5 – 8.6 [8]
sauvagine Mm Full agonist 8.4 – 8.7 pKd 14,28,35
pKd 8.4 – 8.7 [14,28,35]
urotensin 1 (fish) Mm Full agonist 8.5 pKd 35
pKd 8.5 [35]
sauvagine Hs Full agonist 7.6 – 9.3 pKd 8,12
pKd 7.6 – 9.3 [8,12]
sauvagine Rn Full agonist 8.0 – 8.8 pKd 14,28
pKd 8.0 – 8.8 [14,28]
urocortin 3 {Sp: Mouse, Rat} Rn Full agonist 8.3 pKd 22
pKd 8.3 [22]
urotensin 1 (fish) Hs Full agonist 7.3 – 8.9 pKd 12
pKd 7.3 – 8.9 [12]
urocortin 3 {Sp: Human} Hs Full agonist 7.9 – 8.0 pKd 8
pKd 7.9 – 8.0 [8]
urocortin 3 {Sp: Human} Mm Full agonist 7.9 pKd 22
pKd 7.9 [22]
CRF {Sp: Human, Mouse, Rat} Rn Full agonist 7.9 pKd 14
pKd 7.9 [14]
urocortin 3 {Sp: Human} Rn Full agonist 7.7 pKd 22
pKd 7.7 [22]
CRF {Sp: Human, Mouse, Rat} Hs Full agonist 6.5 – 7.4 pKd 12
pKd 6.5 – 7.4 [12]
CRF {Sp: Sheep} Hs Full agonist 5.9 – 6.9 pKd 8,12
pKd 5.9 – 6.9 [8,12]
CRF {Sp: Human, Mouse, Rat} Mm Full agonist 7.8 pKi 14,35
pKi 7.8 [14,35]
View species-specific agonist tables
Agonist Comments
See Table 1 in the 'introduction' for sequences similarities of the common endogenous ligands.

Urocortin 2 and urocortin 3 are highly selective for CRF2 receptors whereas ovine CRF is selective for CRF1 receptors. Urocortin 1 displays high affinity for all CRF1 and CRF2 receptors.

Agonist potencies:
CRF (ovine) (7.0-7.5); CRF (human) (7.5-8.0); urocortin 1 (human) (9.2-10); sauvagine (frog) (9.2-10); urocortin 2 (human and mouse) (8.5-9.5); urocortin 3 (human and mouse) (7.5-8.5) (units: pEC50).
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[125I]antisauvagine Hs Antagonist 9.9 pKd 12
pKd 9.9 [12]
antisauvagine Hs Antagonist 8.8 – 9.6 pKd 12
pKd 8.8 – 9.6 [12]
α-helical CRF Mm Antagonist 9.0 – 9.1 pKd 28
pKd 9.0 – 9.1 [28]
astressin Mm Antagonist 9.0 pKd 28
pKd 9.0 [28]
astressin Hs Antagonist 8.8 – 8.9 pKd 12
pKd 8.8 – 8.9 [12]
astressin Rn Antagonist 8.6 – 8.8 pKd 28
pKd 8.6 – 8.8 [28]
α-helical CRF Rn Antagonist 8.3 – 8.4 pKd 28
pKd 8.3 – 8.4 [28]
[125I]astressin Hs Antagonist 9.6 – 9.7 pKi 8,12
pKi 9.6 – 9.7 [8,12]
K41498 Hs Antagonist 9.2 pKi 21
pKi 9.2 [21]
K31440 Hs Antagonist 8.7 – 8.8 pKi 30
pKi 8.7 – 8.8 [30]
View species-specific antagonist tables
Primary Transduction Mechanisms
Transducer Effector/Response
Gs family Adenylate cyclase stimulation
References:  7,18,20,22-23,25,27,32,34
Secondary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
Comments:  So far only conclusively shown for recombinant expression systems
References:  8
Tissue Distribution
Discrete expression of CRF2 mRNA in limbic structures that are involved in stress responses. In ther periphery widespread expression, especially in heart, skeletal muscle and lung
Species:  Rat
Technique:  immunocytochemistry.
References:  5,24
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
VIP2.OZc cells stably transfected with human CRF2 cDNA.
Species:  Human
Tissue:  VIP2.OZc
Response measured:  increase of cAMP-stimulated beta galactosidase expression
References:  23
HEK 293 and SK-N-MC cells stably transfected with CRF2.
Species:  Human
Tissue:  HEK 293, SK-N-MC cells.
Response measured:  Increase of intracellular cAMP.
References:  8,12
Physiological Functions
Anxiety-like behaviors and stress responses mediated by CRF1 receptor activation in the central nervous system have been shown to be decreased when brain CRF2 receptors are also activated by agonists. Other studies suggest the brain CRF2 receptor activation may lead to a delayed anxiolytic effect.
Species:  Mouse
Tissue:  Brain
References:  1,4,16,19,33
Potent inotropic and lusitropic effects and a reduction of systemic arterial pressure are produced when cardiac CRF2 receptors are activated by a urocortin 2 infusion. Urocortin 2 injected into mice with heart failure results in CRF2 receptor-mediated inotropic and lusitropic effects on left ventricular function and improved cardiac output.
Species:  Mouse
Tissue:  Heart
References:  3
CRF2 receptor mechanisms were found to be critical for tonic inhibition of adult neovascularization.
Species:  Mouse
Tissue:  Arteries
References:  2
Secretion of insulin and glucagon by islet cells was increased in rats by a urocortin 3 infusion via a CRF2 receptor mechanism.
Species:  Rat
Tissue:  Pancreas
References:  6
Physiological Consequences of Altering Gene Expression
Increased anxiety-like behavior in CRF2-deficient animals. Animals are hypersensitive to stress.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  1,19
Reduced shock-induced freezing behavior in rats observed after septal infusion of an antisense oligonucleotide. Control animals showed normal anxiety-like behavior.
Species:  Rat
Tissue: 
Technique:  Antisense oligonucleotide.
References:  17
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0005666 abnormal adipose tissue physiology PMID: 12746321 
Crhr1tm1Klee|Crhr2tm1Klee Crhr1tm1Klee/Crhr1tm1Klee,Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:88498  MGI:894312  MP:0001362 abnormal anxiety-related response PMID: 11756502 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0001614 abnormal blood vessel morphology PMID: 12032352 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0002971 abnormal brown adipose tissue morphology PMID: 12746321 
Crhr2tm1Mpsp Crhr2tm1Mpsp/Crhr2tm1Mpsp
involves: 129X1/SvJ * C57BL/6J
MGI:894312  MP:0001431 abnormal eating behavior PMID: 10742107  11337086 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0005449 abnormal food intake PMID: 10742108  12746321 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0002078 abnormal glucose homeostasis PMID: 12746321 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0003953 abnormal hormone level PMID: 10742108 
Crhr1tm1Klee|Crhr2tm1Klee Crhr1tm1Klee/Crhr1tm1Klee,Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:88498  MGI:894312  MP:0003953 abnormal hormone level PMID: 11756502 
Crhr2tm1Mpsp Crhr2tm1Mpsp/Crhr2tm1Mpsp
involves: 129X1/SvJ * C57BL/6J
MGI:894312  MP:0003953 abnormal hormone level PMID: 10742107 
Crhr2tm1Mpsp Crhr2tm1Mpsp/Crhr2tm1Mpsp
involves: 129X1/SvJ * C57BL/6J
MGI:894312  MP:0004215 abnormal myocardial fiber physiology PMID: 10742107 
Crhr2tm1Mpsp Crhr2tm1Mpsp/Crhr2tm1Mpsp
involves: 129X1/SvJ
MGI:894312  MP:0001360 abnormal social investigation PMID: 20610744 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0000230 abnormal systemic arterial blood pressure PMID: 10742108 
Crhr2tm1Jsp Crhr2tm1Jsp/Crhr2tm1Jsp
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
MGI:894312  MP:0001619 abnormal vascular permeability PMID: 10742109 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0002970 abnormal white adipose tissue morphology PMID: 12746321 
Crhr1tm1Klee|Crhr2tm1Klee Crhr1tm1Klee/Crhr1tm1Klee,Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:88498  MGI:894312  MP:0008294 abnormal zona fasciculata morphology PMID: 11756502 
Crhr1tm1Klee|Crhr2tm1Klee Crhr1tm1Klee/Crhr1tm1Klee,Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:88498  MGI:894312  MP:0000640 adrenal gland hypoplasia PMID: 11756502 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0002573 behavioral despair PMID: 12832554 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0005179 decreased circulating cholesterol level PMID: 12746321 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0002702 decreased circulating free fatty acid level PMID: 12746321 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0002644 decreased circulating triglyceride level PMID: 12746321 
Crhr2tm1Mpsp Crhr2tm1Mpsp/Crhr2tm1Mpsp
involves: 129X1/SvJ * C57BL/6J
MGI:894312  MP:0001442 decreased grooming behavior PMID: 10742107 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0010025 decreased total body fat amount PMID: 12746321 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0002757 decreased vertical activity PMID: 12746321 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0000231 hypertension PMID: 12032352 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0005601 increased angiogenesis PMID: 12032352 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0001363 increased anxiety-related response PMID: 10742108 
Crhr2tm1Jsp Crhr2tm1Jsp/Crhr2tm1Jsp
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
MGI:894312  MP:0001363 increased anxiety-related response PMID: 10742109 
Crhr2+|Crhr2tm1Jsp Crhr2tm1Jsp/Crhr2+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
MGI:894312  MP:0001363 increased anxiety-related response PMID: 10742109 
Crhr2tm1Klee Crhr2tm1Klee/Crhr2tm1Klee
involves: 129S4/SvJae * C57BL/6
MGI:894312  MP:0002891 increased insulin sensitivity PMID: 12746321 
Crhr2tm1Mpsp Crhr2tm1Mpsp/Crhr2tm1Mpsp
involves: 129X1/SvJ * C57BL/6J
MGI:894312  MP:0002842 increased systemic arterial blood pressure PMID: 10742107 
Biologically Significant Variants
Type:  Splice variants.
Species:  Human
Description:  Three biologically important variants, CRF2(a-c) have been reported in humans. Splicing seems to affect tissue distribution but has no effect on the pharmacological and biological properties of the CRF2 receptor. The CRF2(a) variant is the predominant peripheral and central receptor.
References:  10,20,23,34
Type:  Splice variants.
Species:  Rat
Description:  Two biologically important variants, CRF2(a-b) have been reported in rodents and primates. Splicing seems to affect tissue distribution but has no effect on the pharmacological and biological properties of the CRF2 receptor.
References:  25
General Comments
There is a wider distribution of CRF2 mRNA in the brain of rhesus monkey and tree shrew than in rodents. Overlapping expression with the CRF1 receptor found in the neocortex and pituitary.
Technique: Immunocytochemistry
References: [27,31]

The widespread expression of CRF2 in humans and primates so far has hampered a clear cut view on the physiological role of this receptor. Furthermore, pharmacological studies using specific peptide antagonists and transgenic studies have revealed discrepant data. To date it is not certain whether activation or blockade of the receptor might have a positive or negative impact on affective spectrum disorders.[9,11,15,33]
Available Assays
DiscoveRx PathHunter® CHO-K1 CRHR2 β-Arrestin Cell Line (Cat no. 93-0251C2)
PathHunter® eXpress CRHR2 CHO-K1 β-Arrestin GPCR Assay (Cat no. 93-0251E2CP0M)
more info

REFERENCES

1. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, Lee KF. (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet.24: 410-414. [PMID:10742108]

2. Bale TL, Giordano FJ, Hickey RR, Huang Y, Nath AK, Peterson KL, Vale WW, Lee K-F. (2002) Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci U S A.99: 7734-7739. [PMID:12032352]

3. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee K-F, Rivier J, Chien KR, Vale WW, Peterson KL. (2004) The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci U S A.101: 3697-3702. [PMID:14990799]

4. Bale TL, Vale WW. (2004) CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol.44: 525-557. [PMID:14744257]

5. Chalmers DT, Lovenberg TW, De Souza EB. (1995) Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci.15: 6340-6350. [PMID:7472399]

6. Chien C, Chen P, Vaughan J, Blount A, Chen A, Jamieson PM, Rivier J, Smith MS, Vale W. (2003) Urocortin III is expressed in pancreatic β-cells and stimulates insulin and glucagons secretion. Endocrinology.144: 3216-3224. [PMID:12810578]

7. Dautzenberg FM, Dietrich K, Palchaudhuri MR, Spiess J. (1997) Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor. J Neurochem.69: 1640-1649. [PMID:9326293]

8. Dautzenberg FM, Gutknecht E, Van der Linden I, Olivares-Reyes JA, Dürrenberger F, Hauger RL. (2004) Cell type specific calcium signaling by corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: Gq coupling in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells. Biochem Pharmacol.68: 1833-1844. [PMID:15450949]

9. Dautzenberg FM, Hauger RL. (2002) The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci.23: 71-77. [PMID:11830263]

10. Dautzenberg FM, Huber G, Higelin J, Py-Lang G, Kilpatrick GJ. (2000) Evidence for the abundant expression of arginine 185 containing human CRF(2alpha) receptors and the role of position 185 for receptor-ligand selectivity. Neuropharmacology.39: 1368-1376. [PMID:10818253]

11. Dautzenberg FM, Kilpatrick GJ, Hauger RL, Moreau J. (2001) Molecular biology of the CRH receptors-- in the mood. Peptides.22: 753-760. [PMID:11337088]

12. Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G. (2001) Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences. J Pharmacol Exp Ther.296: 113-120. [PMID:11123370]

13. Dautzenberg FM, Wille S. (2004) Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism. Regul Pept.118: 165-173. [PMID:15003833]

14. Donaldson CJ, Sutton SW, Perrin MH, Corrigan AZ, Lewis KA, Rivier JE, Vaughan JM, Vale WW. (1996) Cloning and characterization of human urocortin. Endocrinology.137: 2167-2170. [PMID:8612563]

15. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. (2003) International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev.55: 21-26. [PMID:12615952]

16. Heinrichs SC, Koob GF. (2004) Corticotropin-releasing factor in brain: a role in activation, arousal and affect regulation. J Pharmacol Exp Therap.311: 427-440. [PMID:15297468]

17. Ho SP, Takahashi LK, Livanov V, Spencer K, Lesher T, Maciag C, Smith MA, Rohrbach KW, Hartig PR, Arneric SP. (2001) Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Brain Res Mol Brain Res.89: 29-40. [PMID:11311973]

18. Kishimoto T, Pearse RV2nd, Lin CR, Rosenfeld MG. (1995) A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci U S A.92: 1108-1112. [PMID:7755719]

19. Kishimoto T, Radulovic J, Radulovic M, Line CR, Schrick C, Hooshmand F, Hermanson O, Rosenfeld MG, Spiess J. (2000) Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet.24: 415-419. [PMID:10742107]

20. Kostich WA, Chen A, Sperle K, Largent BL. (1998) Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol.12: 1077-1085. [PMID:9717834]

21. Lawrence AJ, Krstew EV, Dautzenberg FM, Rühmann A. (2002) The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain. Br. J. Pharmacol.136 (6): 896-904. [PMID:12110614]

22. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW. (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A.98: 7570-7575. [PMID:11416224]

23. Liaw CW, Lovenberg TW, Barry G, Oltersdorf T, Grigoriadis DE, De Souza EB. (1996) Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology.137: 72-77. [PMID:8536644]

24. Lovenberg TW, Chalmers DT, Liu C, De Souza EB. (1995) CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology.136: 4139-4142. [PMID:7544278]

25. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, Oltersdorf T. (1995) Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A.92: 836-840. [PMID:7846062]

26. Pal K, Swaminathan K, Xu HE, Pioszak AA. (2010) Structural basis for hormone recognition by the Human CRFR2{alpha} G protein-coupled receptor. J. Biol. Chem.285 (51): 40351-61. [PMID:20966082]

27. Palchaudhuri MR, Hauger RL, Wille S, Fuchs E, Dautzenberg FM. (1999) Isolation and pharmacological characterization of two functional splice variants of corticotropin-releasing factor type 2 receptor from Tupaia belangeri. J Neuroendocrinol.11: 419-428. [PMID:10336722]

28. Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW. (1999) Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther.288: 729-734. [PMID:9918582]

29. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE. (2001) Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A.98: 2843-2848. [PMID:11226328]

30. Rühmann A, Chapman J, Higelin J, Butscha B, Dautzenberg FM. (2002) Design, synthesis and pharmacological characterization of new highly selective CRF(2) antagonists: development of 123I-K31440 as a potential SPECT ligand. Peptides23 (3): 453-60. [PMID:11835994]

31. Sanchez MM, Young LJ, Plotsky PM, Insel TR. (1999) Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol.408: 365-377. [PMID:10340512]

32. Stenzel P, Kesterson R, Yeung W, Cone RD, Rittenberg MB, Stenzel-Poore MP. (1995) Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol Endocrinol.9: 637-645. [PMID:7565810]

33. Takahashi LK. (2001) Role of CRF(1) and CRF(2) receptors in fear and anxiety. Neurosci Biobehav Rev.25: 627-636. [PMID:11801288]

34. Valdenaire O, Giller T, Breu V, Gottowik J, Kilpatrick G. (1997) A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor. Biochim Biophys Acta.1352: 129-132. [PMID:9199241]

35. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C et al.. (1995) Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature.378: 287-292. [PMID:7477349]

To cite this database page, please use the following:

Frank M. Dautzenberg, Dimitri E. Grigoriadis, Richard L. Hauger, Thomas Steckler, Wylie W. Vale.
Corticotropin-releasing factor receptors: CRF2 receptor. Last modified on 05/03/2013. Accessed on 20/09/2014. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=213.

Contact us | Print | Back to top | Help
Copyright © 2014 IUPHAR